U.S. Stem Cell, Inc. Stock Other OTC
Equities
USRM
US90350U1007
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 201K | Sales 2022 | 82.05K | Capitalization | 3.05M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -2M | EV / Sales 2021 | 59.5 x |
Net Debt 2021 | 8.93M | Net Debt 2022 | 10.08M | EV / Sales 2022 | 160 x |
P/E ratio 2021 |
-0.84
x | P/E ratio 2022 |
-0.99
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 17-03-04 |
Director/Board Member | 100 | 03-05-31 | |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |